Tomita T, Yasue M, Engelhard H H, McLone D G, Gonzalez-Crussi F, Bauer K D
Division of Pediatric Neurosurgery, Children's Memorial Hospital, Chicago, IL 60614.
Cancer. 1988 Feb 15;61(4):744-9. doi: 10.1002/1097-0142(19880215)61:4<744::aid-cncr2820610418>3.0.co;2-m.
Paraffin-embedded surgical specimens from 26 infants and children with medulloblastomas treated between 1972 and 1981 were examined for DNA ploidy by flow cytometry (FCM). All patients received a standard treatment (a combination of maximum debulking of medulloblastoma and postoperative craniospinal irradiation with a posterior fossa boost of 5000 rad or more). They were studied to correlate the results of the findings of FCM DNA analysis with their final outcome, DNA ploidy, and extent of tumor resection. All seven patients with totally resected aneuploid medulloblastoma are alive, whereas only one of six patients with subtotally resected diploid medulloblastoma is alive (P = 0.0047). The current study suggests both DNA ploidy and extent of surgical resection are the most important determinant of patients' prognosis. Patients in selected group, particularly those with subtotally resected diploid tumor, are advised to undergo aggressive adjuvant chemotherapy.
对1972年至1981年间接受治疗的26例患有髓母细胞瘤的婴幼儿石蜡包埋手术标本进行了流式细胞术(FCM)DNA倍体检测。所有患者均接受标准治疗(髓母细胞瘤最大程度减瘤与术后颅脊髓照射联合后颅窝加量5000拉德或更高剂量)。对他们进行研究以将FCM DNA分析结果与其最终结局、DNA倍体及肿瘤切除范围相关联。所有7例完全切除非整倍体髓母细胞瘤的患者均存活,而6例次全切除二倍体髓母细胞瘤的患者中只有1例存活(P = 0.0047)。当前研究表明DNA倍体及手术切除范围均是患者预后的最重要决定因素。建议特定组中的患者,尤其是次全切除二倍体肿瘤的患者接受积极的辅助化疗。